

DAFTAR PUSTAKA

1. Sun T, Hall ML, Isbester PK, Whiteheat BR. Fenofibric acid polymorph; methods of making; and methods of use thereof. United State Application Publication. 2009;56(4).
2. Yang LPH, Keating GM. Fenofibric Acid In Combination Therapy in the Treatment of Mixed Dyslipidemia. *J cardiovasc drugs*. 2009;9(6):401–9.
3. Alagona P. A New Fibrate Approved for Use in Cobination With Statin For the Treatment Of Mixed Dyslipidemia. *Vascular Health Risk Management*. 2010;6(1):251–362.
4. Saurav A, Kaushik M, Mohiuddin SM. Fenofibric acid for hyperlipidemia. *Expert Opinion on Pharmacotherapy*. 2012;13(5):717–22.
5. Filippatos TD. A review of time courses and predictors of lipid changes with fenofibric acid-statin combination. *Cardiovascular Drugs and Therapy*. 2012;26(3):245–55.
6. Ling. A Review of Currently Available Fenofibrate and Fenofibric Acid Formulations. *Cardiology Research*. 2013;4(2):47–55.
7. Vogt M, Kunath K, Dressman JB. Dissolution enhancement of fenofibrate by micronization, cogrinding and spray-drying: Comparison with commercial preparations. *European Journal of Pharmaceutics and Biopharmaceutics*. 2008;68(2):283–8.
8. Shukla AK, Bishnoi RS, Dev SK, Khumar M, Fenin V. Review Article : Biopharmaceutical Classification System: Tool based prediction for drug dosage formulation. *Advance Pharm J*. 2017;2(6):204–10.
9. Windriyati YN, Sumirtapura YC, Pamudji JS. Comparative in vitro and in vivo evaluation of fenofibric acid as an antihyperlipidemic drug. *Turkish Journal of Pharmaceutical Sciences*. 2020 Apr 1;17(2):203–10.
10. Hens B, Brouwers J, Corsetti M, Augustijns P. Gastrointestinal behavior of nano- and micro-sized fenofibrate: In vivo evaluation in man and in vitro simulation by assessment of the permeation potential. *European Journal of Pharmaceutical Sciences*. 2015;77:40–7.
11. Umar S, Putri Bandaro N, Anggraini D, Zaini E. Multicomponent Crystal of Fenofibric Acid-Saccharin: Characterization and Antihyperlipidemic Effectiveness. *Advances in health sciences research*. 2021;40:104–9.
12. Yousaf AM, Ramzan M, Shahzad Y, Mahmood T, Jamshaid M. Fabrication and in vitro characterization of fenofibric acid-loaded hyaluronic acid–polyethylene glycol polymeric composites with enhanced drug solubility and dissolution rate. *International Journal of Polymeric Materials and Polymeric Biomaterials*. 2019;68(9):510–5.

13. Windriyati YN, Shabrina A. Disolusi dan karakter fisikokimia asam fenofibrat dalam dispersi padat permukaan dengan sodium starch glycolate. *Jurnal ilmiah cendikia eksakta*. 2019;39–44.
14. Windriyati YN, Sumirtapura YC, Pamudji JS. Dissolution enhancement and physicochemical characterization of fenofibric acid in surface solid dispersion with croscarmellose sodium. *Marmara Pharmaceutical Journal*. 2019;23(2):315–25.
15. Kim KS, Kim JH, Jin SG, Kim DW, Kim DS, Kim JO, et al. Effect of magnesium carbonate on the solubility, dissolution and oral bioavailability of fenofibric acid powder as an alkalising solubilizer. *Archives of Pharmacal Research*. 2016;39(4):531–8.
16. Kim KS, Jin SG, Mustapha O, Yousaf AM, Kim DW, Kim YH, et al. Novel fenofibric acid-loaded controlled release pellet bioequivalent to choline fenofibrate-loaded commercial product in beagle dogs. *International Journal of Pharmaceutics*. 2015;490(1–2):273–80.
17. Mahapatra APK, Patil V, Patil R. Solubility Enhancement of Poorly soluble Drugs by using Novel Techniques : A Comprehensive Review. *International Journal of PharmTech Research*. 2020;13(2):80–93.
18. Nikalje AP. Nanotechnology and its Applications in Medicine. *Medicinal Chemistry*. 2015;5(2):81–9.
19. Yousaf AM, Mustapha O, Kim DW, Kim DS, Kim KS, Jin SG, et al. Novel electrospayed nanospherules for enhanced aqueous solubility and oral bioavailability of poorly water-soluble fenofibrate. *International Journal of Nanomedicine*. 2016;11:213–21.
20. Peltonen L. Practical guidelines for the characterization and quality control of pure drug nanoparticles and nano-cocrystals in the pharmaceutical industry. *Advanced Drug Delivery Reviews*. 2018;131:101–15.
21. Emami S, Siah-Shadbad M, Barzegar-Jalali M, Adibkia K. Characterizing eutectic mixtures of gliclazide with succinic acid prepared by electrospray deposition and liquid assisted grinding methods. *Journal of Drug Delivery Science and Technology*. 2018;45:101–9.
22. Rowe R, Sheskey P, Quinn M. *Handbook of pharmaceutical excipients*. sixth edition. London: the pharmaceutical press; 2009.
23. Alamri RG, Mohsin K, Ahmad A, Raish M, Alanazi FK. Development and validation of bioanalytical UHPLC-UV method for simultaneous analysis of unchanged fenofibrate and its metabolite fenofibric acid in rat plasma: Application to pharmacokinetics. *Saudi Pharmaceutical Journal*. 2017;25(1):128–35.
24. Suhery WN, Sumirtapura YC, Pamudji JS, Mudhakhir D. Development and characterization of self-nanoemulsifying drug delivery system (Snedds) formulation for enhancing dissolution of fenofibric acid. *Journal of Research in Pharmacy*. 2020;24(5):738–47.

25. Zhu T, Awni WM, Hosmane B. ABT-335, the Choline Salt of Fenofibric Acid does not Have Clinically Significant Pharmacokinetic Interaction with Rosuvastatin in Humans. *J Clin Pharmacol*. 2009;49(1):63–71.
26. Tojcic J, Benoit BcMH. In vitro Glucoronidation of Fenofibri Acid by Human UGT's and Liver Microsomes. *Drug Metab Dispos*. 2009;37(11):2236–43.
27. Departemen Kesehatan Indonesia. *Farmakope Indonesia*. VI. Jakarta: Departemen Kesehatan RI; 2020.
28. Baltimor M, editor. *USP 30-NF 25*. USP Convention; 2007.
29. *British Pharmacopea*. 2009.
30. National Center for Biotechnology Information (2022). PubChem Compound Summary for CID 5143, Saccharin. Retrieved February 2, 2022 from <https://pubchem.ncbi.nlm.nih.gov/compound/Saccharin>.
31. Cai L, Jiang L, Li C, Guan X, Zhang L, Hu X. Multicomponent crystal of metformin and barbital: Design, crystal structure analysis and characterization. *Molecules MDPI*. 2021;26(14).
32. Zaini E, Afriyani, Fitriani L, Ismed F, Horikawa A, Uekusa H. Improved solubility and dissolution rates in novel multicomponent crystals of piperine with succinic acid. *Scientia Pharmaceutica MDPI*. 2020;88(2):1–12.
33. Yuliandra Y, Izadihari R, Rosaini H, Zaini E. Multicomponent crystals of mefenamic acid–tromethamine with improved dissolution rate. *Journal of Research in Pharmacy*. 2019;23(6):988–96.
34. Yuliandra Y, Hutabarat LJ, Ardila R, Octavia MD, Zaini E. Enhancing solubility and antibacterial activity using multi-component crystals of trimethoprim and malic acid. *Pharmacy Education*. 2021;21(2):296–304.
35. Sakamoto M, Uekusa H. *Advances in Organic Crystal Chemistry*. Singapore; 2020.
36. Byrn SR, Zografi G, Chen XS. Solvates and Hydrates. In: *Solid State Properties of Pharmaceutical Materials*. 2017.
37. Takeddin K, Khimyak YZ, Fábíán L. Prediction of Hydrate and Solvate Formation Using Statistical Models. *Crystal Growth and Design*. 2016;16(1).
38. Vippagunta SR, Brittain HG, Grant DJW. Crystalline solids. *Advanced Drug Delivery Reviews*. 2001;48(1).
39. Clarke HD. *Crystal Engineering of Multi-Component Crystal Forms: The Opportunities and Challenges in Design*. ProQuest Dissertations and Theses. 2012;

40. Sathisaran I, Dalvi SV. Engineering cocrystals of poorly water-soluble drugs to enhance dissolution in aqueous medium. *Pharmaceutics MDPI*. 2018;10(3).
41. Gosar DA, Hussain DS, Shaikh DT. Polymorphism and polymorph characterisation in pharmaceuticals. *Journal of Biomedical and Pharmaceutical Research*. 2019;8(5):52–9.
42. Tan J, Liu J, Ran L. A review of pharmaceutical nano-cocrystals: A novel strategy to improve the chemical and physical properties for poorly soluble drugs. *Crystals MDPI*. 2021;11(5):1–14.
43. Sopyan I, Alvin B, Insan Sunan KS, Cikra Ikhda NHS. Systematic review: Cocrystal as efforts to improve physicochemical and bioavailability properties of oral solid dosage form. *International Journal of Applied Pharmaceutics*. 2021;13(1):43–52.
44. Guo M, Sun X, Chen J, Cai T. Pharmaceutical cocrystals: A review of preparations, physicochemical properties and applications. *Acta Pharmaceutica Sinica B*. 2021;11(8):2537–64.
45. Shaikh R, Singh R, Walker GM, Croker DM. Pharmaceutical Cocrystal Drug Products: An Outlook on Product Development. *Trends in Pharmacological Sciences*. 2018;39(12):1033–48.
46. Gao Y, Gao J, Liu Z, Kan H, Zu H, Sun W, et al. Cofomer selection based on degradation pathway of drugs: A case study of adefovir dipivoxil-saccharin and adefovir dipivoxil-nicotinamide cocrystals. *International Journal of Pharmaceutics*. 2012 Nov 15;438(1–2):327–35.
47. Buddhadev SS, Garala KC. Pharmaceutical Cocrystals—A Review. *Proceedings MDPI*. 2021;62(1):1–14.
48. Cherukuvada S, Nangia A. A Eutectics as Improved Pharmaceutical Materials: Design, Properties and Characterization. *Chem commun*. 2014;50:906–23.
49. Chavan RB, Shastri NR. Overview of Multicomponent Solid Forms. *Journal of Nanotoxicology and Nanomedicine*. 2019;3(1):23–48.
50. Moore MD, Wildfong PL. Aqueous solubility enhancement through engineering of binary solid composites: pharmaceutical application. *Journal Pharm Innov*. 2009;4:36–49.
51. Bazzo GC, Pezzini BR, Stulzer HK. Eutectic mixtures as an approach to enhance solubility, dissolution rate and oral bioavailability of poorly water-soluble drugs. *International Journal of Pharmaceutics*. 2020;588.
52. Bijay K, Atif K, Rattan D. Cocrystal: a complete review on conventional and novel methods of its formation and its evaluation. *Asian Journal of Pharmaceutical and Clinical Research*. 2019;12(7):68–74.
53. Parida K, Panda S, Ravanan P, Roy H, Manickam M, Talwar P. Microparticles based drug delivery system: preparation and application in

- cancer therapeutics. *International archieve of applied science and technology*. 2013;40(3):2277–1565.
54. Khadka P, Ro J, Kim H, Kim I, Kim JT, Kim H, et al. Pharmaceutical particle technologies: An approach to improve drug solubility, dissolution and bioavailability. *Asian Journal of Pharmaceutical Sciences*. 2014;9(6):304–16.
 55. Fatmawaty A, Nisa M, Riski R. *Teknologi Sediaan Farmasi*. Yogyakarta: Deepublish Publisher; 2019.
 56. Fontana F, Figueiredo P, Zhang P, Santos H, Liu D, Hirvonen J. Production of pure drug nanocrystals and nano co-crystals by confinement methods. *Adv Drug Deliv Rev*. 2018;3(21):3–21.
 57. Möschwitzer J. Nanotechnology: Particle Size Reduction Technologies in the Pharmaceutical Development Process. *particle sizing*. 2010;54–9.
 58. Tuomela A, Hirvonen J, Peltonen L. Stabilizing agents for drug nanocrystals: Effect on bioavailability. *Pharmaceutics*. 2016;8(2).
 59. Patel J, Sandeep K. Development of Nanocrystal Formulation With Improved Dissolution. *J Drug Deliv Ther*. 2018;9(4):59–69.
 60. Pardhi VP, Verma T, Flora SJS, Chandasana H, Shukla R. Nanocrystals: An Overview of Fabrication, Characterization and Therapeutic Applications in Drug Delivery. *Current Pharmaceutical Design*. 2019;24(43):5129–46.
 61. Peltonen L, Valo H, Kolakovic R, Laaksonen T, Hirvonen J. Electrospraying, spray drying and related techniques for production and formulation of drug nanoparticles. *Expert Opinion on Drug Delivery*. 2010;7(6):705–19.
 62. Savjani KT, Gajjar AK, Savjani JK. Drug Solubility: Importance and Enhancement Techniques. *ISRN Pharmaceutics*. 2012;1–10.
 63. Kurniawan DW, Sulaiman TN. *Teknologi Sediaan Farmasi*. Yogyakarta: Graha Ilmu; 2009.
 64. Patel RP, Patel MP, Suthar AM. Spray drying technology: an overview. *Indian Journal of Science and Technology* [Internet]. 2009;2(10):44–7. Available from: <http://www.indjst.org/IndianJ.Sci.Technol>.
 65. Wong T, John P. Advances in spray drying technology for nanoparticle formation. Aliofkhazraei M, editor. New York; 2015. 1–16 p.
 66. Miller DA, Ellenberger D, Gil M. Spray-drying technology. In: *AAPS Advances in the Pharmaceutical Sciences Series*. 2016.
 67. Savjani KT, Gajjar AK, Savjani JK. Drug Solubility: Importance and Enhancement Techniques. *ISRN Pharmaceutics*. 2012 Jul 5;2012:1–10.
 68. Lachman L, Lieberman H, Kanig JL. *Teori dan Praktek Farmasi Industri*. edisi ke-3. 1986.

69. Vemula VR, Lagishetty V, Lingala S. Solubility Enhancement Techniques. *J Pharm Sciences Review and Research*. 2010;5(1):41–51.
70. Sinko P, editor. *Martin's Physical Pharmacy and Pharmaceutical Sciences*. Philadelphia: Lippincott William and Wilkins; 2011.
71. Thapa RK, Choi HG, Kim JO, Yong CS. Analysis and optimization of drug solubility to improve pharmacokinetics. *Journal of Pharmaceutical Investigation*. 2017;47(2):95–110.
72. Basanta Kumar Reddy B, Karunakar A. Biopharmaceutics classification system: A regulatory approach. *Dissolution Technologies*. 2011;18(1):31–7.
73. Kumar S, Singh P. Various techniques for solubility enhancement: an overview. *the pharma innovation journal* [Internet]. 2016;5(1):23–8. Available from: www.thepharmajournal.com
74. Sahoo SK. Enhancement of solubility: A pharmaceutical overview. *Scholar research library* [Internet]. 2010;2(2):310–8. Available from: <https://www.researchgate.net/publication/283997580>
75. Kadam S v, Shinkar DM, Saudagar RB. Review on solubility enhancement techniques. *International Journal of Pharmacy and Biological Sciences* [Internet]. 2013;3(3):2230–7605. Available from: www.ijpbs.com or www.ijpbsonline.com
76. de Fátima É, Oliveira S, de Cássia R, Azevedo P, Bonfilio R, Borges De Oliveira D, et al. Dissolution test optimization for meloxicam in the tablet pharmaceutical form. *Brazilian Journal of Pharmaceutical Sciences*. 2009;45(1):67–73.
77. Zaborenko N, Shi Z, Corredor CC, Smith-Goettler BM, Zhang L, Hermans A, et al. First-Principles and Empirical Approaches to Predicting In Vitro Dissolution for Pharmaceutical Formulation and Process Development and for Product Release Testing. *AAPS Journal*. 2019;21(3).
78. Siregar C. *Teknologi Farmasi Sediaan Tablet*. Jakarta: EGC; 2010.
79. Dressman J, Krämer J. *Pharmaceutical dissolution testing. Pharmaceutical Dissolution Testing*. 2005.
80. Han E, goleman daniel. *Pharmaceutical Dissolution Testing. Journal of Chemical Information and Modeling*. 2019;53(9):289–99.
81. Sugita P, Bintang M, Achmadi SS, Pradono DI, Irawadi TT, Darusman LK. *Segi Kimiawi dan Biokimiawi dari Sistem Pengantaran Obat*. Bogor: IPB; 2018.
82. Shargel L, Wu-Pong S. *Applied Biopharmaceutics and Pharmacokinetics*.
83. Agrawal Y, Patel V. Nanosuspension: An approach to enhance solubility of drugs. *Journal of Advanced Pharmaceutical Technology & Research*. 2011;2(2):81.

84. Setiabudi ARHAM. Karakterisasi Material: Prinsip dan Aplikasinya dalam Penelitian Kimia. Vol. 1, UPI Press. 2012.
85. Chandra Gupta P, Yadav S, Sharma N, Kumar J. International journal of pharmaceutical, chemical and biological sciences physicochemical properties of drugs. IJPCBS [Internet]. 2015(2):427–36. Available from: www.ijpcbs.com
86. Dachriyanus. Analisis Struktur Senyawa Organik Secara Spektroskopi. Padang: LPTIK; 2004.
87. Sudjadi. Kimia Farmasi Analisis. Yogyakarta: Pustaka Belajar; 2012.
88. Harmita. Analisis Fisikokimia Kromatografi. Jakarta: EGC; 2009.
89. Meyer VR. Practical High-Performance Liquid Chromatography: Fifth Edition. Practical High-Performance Liquid Chromatography: Fifth Edition. 2010.
90. Susanti M, Dachriyanus. Kromatografi Cair Kinerja Tinggi. Padang: LPTIK; 2017.
91. Liu P. Nanocrystal formulation for poorly soluble drugs. 2013;
92. Anggraini D, Umar S, Arifin H, Zaini E. Dissolution rate enhancement and physicochemical characterization of a fenofibric acid–nicotinamide eutectic mixture. Tropical Journal of Natural Product Research. 2021;5(9):1614–8.
93. Kamus Besar Bahasa Indonesia (KBBI).
94. Sosnik A, Seremeta KP. Advantages and challenges of the spray-drying technology for the production of pure drug particles and drug-loaded polymeric carriers. Vol. 223, Advances in Colloid and Interface Science. 2015.
95. Silfia S, Failisnur F, Sofyan S. Analysis of Functional Groups, Distribution, and Particle Size of Stamp Ink From Gambier (*Uncaria gambir* Roxb) With NaOH and Al₂(SO₄)₃ Complexing Compounds. Jurnal Litbang Industri. 2019;9.
96. Zaini E, Halim A, Soeandhi S, Setyawan D. Peningkatan laju pelarutan trimetropim melalui metode ko-kristalisasi dengan nikotinamida. Jurnal farmasi Indonesia. 2011;5:205–12.
97. Gozali D, Tandela R, Wardhana Y. Karakterisasi dan peningkatan disolusi kalsium atorvastatin melalui proses mikrokristalisasi . Bionatura-Jurnal ilmu-ilmu hayati dan fisik. 2014;16(1):16–20.
98. Wardiyah asyarie, Wikarsa S. Pembuatan dan karakterisasi dispersi padat sistem biner dan terner dari gliklazid. Acta pharmaceutica indonesia. 2012;73(3):95–101.
99. Sastrohamidjojo hardjono. dasar-dasar spektroskopi. Yokyakarta: UGM Press; 2013.

100. Variankaval N, McNevin M, Shultz S, Trzaska S. High-Throughput Screening to Enable Salt and Polymorph Screening, Chemical Purification, and Chiral Resolution. In: Comprehensive Organic Synthesis: Second Edition. 2014.
101. Synder R, Kirkland J, Dolan J. introducing to modern liquid chromatography. 2010.
102. Mirza RM, Ahirrao SP, Kshirsagar SJ. a Nanocrystal Technology: To Enhance Solubility of Poorly Water Soluble Drugs. Journal of Applied Pharmaceutical Research. 2017;5(1).

